These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32573825)

  • 1. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy.
    Singh S; Kim J; Zhu W; Dulai PS; Sandborn WJ; Jairath V
    Aliment Pharmacol Ther; 2020 Aug; 52(3):481-491. PubMed ID: 32573825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
    Picetti D; Kim J; Zhu W; Sandborn WJ; Jairath V; Singh S
    Dig Dis Sci; 2022 Jul; 67(7):3115-3123. PubMed ID: 34797442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
    Ungaro RC; Limketkai BN; Jensen CB; Allin KH; Agrawal M; Ullman T; Colombel JF; Jess T
    Gut; 2019 Jun; 68(6):977-984. PubMed ID: 30420398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.
    Seo J; Kim S; Hong SW; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Kim YJ; Ye BD
    Aliment Pharmacol Ther; 2024 Aug; 60(3):389-400. PubMed ID: 38866064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study.
    Mak JWY; Yuen NTK; Yip TCF; Lam RHM; Lam BKH; Cheng CTY; Wong GLH; Chan FKL; Ng SC
    J Gastroenterol Hepatol; 2022 Jul; 37(7):1284-1289. PubMed ID: 35338526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.
    Mitra D; Hodgkins P; Yen L; Davis KL; Cohen RD
    BMC Gastroenterol; 2012 Sep; 12():132. PubMed ID: 23006789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial.
    Balram B; Joshi H; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Baumgart DC; Peerani F
    Dig Dis Sci; 2021 Nov; 66(11):3985-3992. PubMed ID: 33184796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
    Shaffer SR; Huang E; Patel S; Rubin DT
    Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
    Rubin DT; Mody R; Davis KL; Wang CC
    Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard treatment of ulcerative colitis.
    Gionchetti P; Rizzello F; Habal F; Morselli C; Amadini C; Romagnoli R; Campieri M
    Dig Dis; 2003; 21(2):157-67. PubMed ID: 14571113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
    Le Berre C; Roda G; Nedeljkovic Protic M; Danese S; Peyrin-Biroulet L
    Expert Opin Biol Ther; 2020 Apr; 20(4):363-378. PubMed ID: 31498003
    [No Abstract]   [Full Text] [Related]  

  • 12. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
    Nagahori M; Kochi S; Hanai H; Yamamoto T; Nakamura S; Omuro S; Watanabe M; Hibi T;
    BMC Gastroenterol; 2017 Apr; 17(1):47. PubMed ID: 28390410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Corticosteroids with 5-Aminosalicylic Acids Compared to Corticosteroids Alone for Hospitalized Patients with Active Ulcerative Colitis.
    Har-Noy O; Kim B; Haiat R; Engel T; Ungar B; Eliakim R; Ho Kim W; Hee Cheon J; Ben-Horin S
    Isr Med Assoc J; 2016 Oct; 18(10):613-618. PubMed ID: 28471622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
    Lakatos L; Lakatos PL
    Orv Hetil; 2007 Jun; 148(25):1163-70. PubMed ID: 17573252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.
    Singh S; Proudfoot JA; Dulai PS; Jairath V; Fumery M; Xu R; Feagan BG; Sandborn WJ
    Am J Gastroenterol; 2018 Aug; 113(8):1197-1205. PubMed ID: 29925913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of aminosalicylates in the treatment of ulcerative colitis.
    Van Assche G; Baert F; De Reuck M; De Vos M; De Wit O; Hoang P; Louis E; Mana F; Pelckmans P; Rutgeerts P; Van Gossum A; D'Haens G
    Acta Gastroenterol Belg; 2002; 65(4):196-9. PubMed ID: 12619425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects.
    Park SK; Ye BD; Yang SK; Kim SO; Kim J; Kim JW; Park SH; Yang DH; Jung KW; Kim KJ; Byeon JS; Myung SJ; Kim JH
    J Crohns Colitis; 2014 Oct; 8(10):1254-60. PubMed ID: 24662395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis.
    Zeisler B; Lerer T; Markowitz J; Mack D; Griffiths A; Bousvaros A; Keljo D; Rosh J; Evans J; Kappelman M; Otley A; Kay M; Grossman A; Saeed S; Carvalho R; Oliva-Hemker M; Faubion W; Sudel B; Pfefferkorn M; Ashai-Khan F; Leleiko N; Hyams J;
    J Pediatr Gastroenterol Nutr; 2013 Jan; 56(1):12-8. PubMed ID: 22847466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis.
    Lee HJ; Jung ES; Lee JH; Hong SP; Kim TI; Kim WH; Cheon JH
    Hepatogastroenterology; 2012; 59(117):1415-20. PubMed ID: 22683958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.
    Rubenstein JH; Waljee AK; Jeter JM; Velayos FS; Ladabaum U; Higgins PD
    Am J Gastroenterol; 2009 Sep; 104(9):2222-32. PubMed ID: 19491824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.